Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Overweight on Accenture, Lowers Price Target to $325

Morgan Stanley analyst James Faucette maintains Accenture (NYSE:ACN) with a Overweight and lowers the price target from $340 to $325.

byBenzinga Newsdesk

March 15, 2023

1 minute read

Morgan Stanley analyst James Faucette maintains Accenture (NYSE:ACN) with a Overweight and lowers the price target from $340 to $325.

Goldman Sachs Downgrades Zymergen to Neutral, Lowers Price Target to $12

By Benzinga Newsdesk

Today, 4:29 PM

Goldman Sachs analyst Matthew Sykes downgrades Zymergen (NASDAQ:ZY) from Buy to Neutral and lowers the price target from $55 to $12.

Did Umbilical Cord Blood Transplant Help Cure A Woman’s HIV infection?

By Vandana Singh

Today, 4:29 PM

A woman in the New York City area appears to have been cured of an HIV infection, Wall Street Journal reported, provid

Analyst Ratings

Where Tesla Stands With Analysts

By Benzinga Insights

Today, 4:29 PM

Within the last quarter, Tesla (NASDAQ:TSLA) has observed the following analyst ratings:

TSLA

Blink Charging Co. Reports Supply Deal With GM Car Dealerships Across North America, No Terms Disclosed

By Benzinga Newsdesk

Today, 4:29 PM

Deployment of Blink’s EV chargers across GM’s dealerships will help support accelerated adoption of EVs Miami Beach, FL, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Blink Charging Co. (NASDAQ:BLNK, BLNKW))

BLNK

Morgan Stanley Maintains Overweight on Accenture, Lowers Price Target to $325

Related Posts

Goldman Sachs Downgrades Zymergen to Neutral, Lowers Price Target to $12

Did Umbilical Cord Blood Transplant Help Cure A Woman’s HIV infection?

Where Tesla Stands With Analysts

Blink Charging Co. Reports Supply Deal With GM Car Dealerships Across North America, No Terms Disclosed